Proposed Heparin Binding Site in Antithrombin Based on Arginine 47

A New Variant Rouen-II, 47 Arg to Ser

J. Y. Borg, M. C. Owen, C. Soria, J. Soria, J. Caen, and R. W. Carrell

Laboratoire d'Hémostase, Centre Hospitalier Universitaire Rouen 76038 Cedex, France; Molecular Pathology Laboratory, Department of Clinical Biochemistry, Christchurch Hospital, Christchurch, New Zealand; Unité de Recherches de Thrombose Expérimentale et Hémostase, Unité 150 Institut National de la Santé et de la Recherche Médicale, Hôpital Lariboisière 75475 Paris, France; and Haematology Department, University of Cambridge, Cambridge CB2 2QL, United Kingdom

Abstract

Antithrombin Rouen-II, a new inherited variant of antithrombin-III, was found in two members of a family with no definite history of thrombosis. The subjects had normal antigenic concentrations of antithrombin and normal progressive inhibitory activity. However, the variant had defective heparin and heparan sulfate cofactor activities, and was not activated by a synthetic pentasaccharide representing the minimum heparin sequence.

The abnormal antithrombin was isolated using heparin-Sepharose chromatography, and on electrophoresis at pH 8.6 migrated more anodally than normal. Two-dimensional peptide mapping of tryptic and *Staphylococcus aureus* V8 protease digests was performed and the abnormal peptide was located by tryptophan staining. Amino acid sequence studies demonstrated a substitution of arginine at residue 47 by a serine.

Evidence strongly suggests that arginine 47 is a prime heparin binding site in antithrombin and that it forms part of a proposed positively charged linear site (to which heparin binds) that stretches across the surface of the molecule from the A to the D helix.

Introduction

Antithrombin (antithrombin-III) a member of the serpin superfamily (1), is the major inhibitor of thrombin and several other coagulation serine proteases. It plays an important physiological role in controlling the coagulation cascade. Inherited quantitative deficiencies of antithrombin result in an increased risk of thromboembolic disease (2).

The formation of the inactive protease-antithrombin complexes is greatly accelerated by commercial heparins or by endothelial, heparin-like substances (3) which are most likely to be one of the heparan sulfates (4).

The mechanism by which heparin activates the protease inhibitory activity of antithrombin remains puzzling, but

some illuminating data have recently emerged. The antithrombin binding sequence in heparin is a unique specific pentasaccharide (5) bearing at least four sulfate groups that play an essential role in this interaction (6). On the other hand, the localization of the heparin binding site on antithrombin remains uncertain. The first clues have come either from chemically modified antithrombins or from molecular characterization of natural mutant inhibitors. In vitro alteration of the tryptophan 49 (7) or of lysine residues (8) prevent the heparin acceleration of the inhibitory activity without affecting the progressive protease inhibitor interaction when the mucopolysaccharide is absent. Only five variants of antithrombin with impaired heparin binding ability have been extensively studied. In four of them, arginine at residue 47 is replaced either by a cysteine in antithrombin Toyama (9), Tours (10), and Alger (11), or by a histidine in the variant Rouen-I we recently reported (12). The fifth one, antithrombin Basel, has a Pro to Leu substitution at residue 41 (13).

We describe in this paper the qualitative investigations and the molecular characterization of a new inherited antithrombin mutant, Rouen-II. Rouen-II has normal progressive inhibitory activity but defective heparin binding and low heparin and heparan sulfate cofactor activities which occur as a result of the replacement of arginine 47 by serine. This variant provides new evidence that arginine 47 is a prime site in antithrombin for the binding of heparin and endothelial mucopolysaccharides.

Methods

Case report. The propositus, a 40-yr-old man suffering from hypertriglyceridemia, was admitted to hospital because of a sudden myocardial infarction that lacked extensive coronary artery disease (this was found out through angiography). As a result of standard investigations he was found to have an abnormal antithrombin. There was no previous familial history of thrombosis, but his 13-yr-old daughter displayed the same antithrombin abnormality.

Antithrombin measurements in plasma. Antithrombin concentration was quantified by Laurell electroimmunoassay (14). Qualitative determinations were carried out by amidolytic methods using synthetic chromogenic substrates of thrombin (IIa) or Factor Xa. Progressive anti-IIa activity was assayed with S2238 from Kabi (Flow, Puteaux, France) and human IIa, as proposed by Aiach (15), progressive anti-Xa activity was evaluated with CBS 3139 (Serbio, Asnières, France) according to Odegard (16). Antithrombin activity was evaluated in the presence of heparin using the reagent kit of Diagnostica Stago (Asnières, France) on a discrete analyzer as recommended by Aiach (17): 5 μ l of plasma were diluted in 500 μ l of pH 8.7, Tris buffer

Address all correspondence to Dr. J. Y. Borg, Laboratoire d'Hémostase, Hôpital Charles Nicolle, 76038 Rouen, Cedex, France.

Received for publication 26 October 1987 and in revised form 12 January 1988.

J. Clin. Invest.

© The American Society for Clinical Investigation, Inc.

0021-9738/88/04/1292/05 \$2.00

Volume 81, April 1988, 1292-1296

containing an excess of bovine thrombin and 3 IU/ml heparin. After a 20-s incubation time, 100 μ l of chromo-thrombin was added and the increase in absorbance recorded during 40 s. Antithrombin activity was also measured in the presence of purified heparan sulfate (HS IIa), obtained from B. Casu (18), using an end-point method: 200 μ l of plasma (diluted 1:10 in Tris-EDTA buffer, pH 8.4, containing 2.25 US Pharmacopeia U/ml heparan sulfate) were incubated with 200 μ l bovine thrombin during 30 s; 200 μ l of CBS 3447 was added and the reaction was stopped after 60 s. Anti-Factor Xa activity was evaluated in the presence of 3 IU/ml heparin or 1 I.C. anti-Xa U/ml synthetic pentasaccharide (IC 851589; a gift from Institut Choay, Paris, France) with the same conditions as for heparan sulfate cofactor activity, but in the presence of bovine Factor Xa and CBS 3139 (from Stachrom heparin reagent kit, Diagnostica Stago). Results are expressed in percentage of control plasma, which comprised a pool of 20 normal plasmas.

Crossed immunoelectrophoresis of antithrombin. This was achieved according to Sas' method (19), with or without the addition in the first dimension of 25 IU/ml unfractionated heparin or of 25 anti-Xa I.C. U/ml low molecular weight heparin (CY 222; Institut Choay, mean molecular weight, 2,500).

Purification and characterization of antithrombin. Antithrombin was isolated on heparin-Sepharose as previously described (12). Electrophoresis on agarose and SDS polyacrylamide, ^{14} C-carboxymethylation and proteolytic digestion with trypsin and *S. aureus* V8 protease, thin layer peptide mapping, HPLC peptide separations, and peptide sequencing were performed as previously described (12).

Antithrombin activation studies. These were performed using purified normal and propositus antithrombins, adjusted to equal antigenic concentration by varying both the heparin concentration (0.1, 0.5, 5.0 IU) and the ionic strength of the phosphate buffer, pH 7.4 (isotonic, 2 $\times$ isotonic, 3 $\times$ isotonic). 0.2 μ g of purified antithrombin was added to 600 μ l of buffer, pH 7.4, which contained heparin. Excess thrombin (10 μ l of Parke Davis, Detroit, topical bovine thrombin diluted 15 μ l to 1 ml) was added and, after 20 min, 25 μ l of Chromozym-TH (5 mg/ml) was added and the increase in absorbance was monitored at 405 nm.

Results

The propositus and his daughter both demonstrated the same antithrombin abnormality in their plasmas (Table I). Immunoreactive levels and progressive activities of antithrombin were within the normal range, whereas heparin cofactor activities measured by antithrombin or anti-Factor Xa assays were decreased to 64–70% of the control, and heparan sulfate co-

factor activity evaluated by an anti-IIa measurement was equally low at 60 and 68%, respectively, of the control. In the same way, the pentasaccharide only partially potentiated inhibition of Factor Xa in the patient's plasma.

Normal patterns were obtained by crossed immunoelectrophoresis in the absence of heparin. But in the presence of unfractionated heparin or low molecular weight heparin, normal antithrombin migrated as a major, more anodal peak, while both abnormal plasmas displayed a double-peak pattern; one peak had the same fast mobility as the control, the other had the same slower migration as antithrombin in the absence of heparin (gels not shown).

The results of heparin-Sepharose chromatography of the patient's plasma at pH 7.4 show heterozygosity for an antithrombin of decreased heparin binding affinity (Fig. 1). The variant antithrombin eluted with 0.45 mol/liter NaCl compared with the normal antithrombin which eluted at 0.95 mol/liter. Quantitation by electroimmunoassay confirmed the presence of an excess of variant compared with the normal component (Table II). The activities of the two separate fractions were also compared (as seen on Table II) using the experimental conditions described for the plasma measurements. The abnormal fraction had normal progressive inhibition activity but defective heparin or pentasaccharide cofactor activities.

The thrombin inhibitory activity of purified Rouen-II and normal antithrombin were compared in PBS that was two or three times its isotonic strength with varying amounts of heparin (Fig. 2). This showed that the variant antithrombin was incompletely activated in the presence of low levels of heparin when there was sufficient competition from the sodium and chloride ions for the charged groups on heparin and antithrombin. At the concentrations of heparin used in the experiment there was no significant difference between Rouen-II and normal antithrombin-III under isotonic conditions. However, at 2 $\times$ isotonic concentration Rouen-II showed < 50% activity at the low heparin level. The difference in activity between normal antithrombin and Rouen-II is even more dramatic in 3 $\times$ isotonic strength buffer. Here Rouen-II with 5.0 U of heparin had less activity than normal antithrombin with 0.5 U of heparin.

Electrophoresis in agarose at pH 8.6 showed that the abnormal antithrombin migrated faster (more anodally) than normal, implying that the variant had an increased negative charge. SDS-PAGE showed the molecular weight of normal and abnormal antithrombins to be identical at 56,000.

A series of peptide maps were prepared of both the normal and abnormal antithrombins. These were identical apart from a consistent finding in both tryptic and V8 protease maps of a shifted tryptophan-containing peptide. Normal tryptic maps

Table I. Antithrombin Levels* in the Propositus and Daughter's Plasma

	Propositus	Daughter	Normal range
Antithrombin antigen	102	115	80–120
Progressive anti-IIa activity	100	122	80–120
Progressive anti-Xa activity	120	100	78–114
Heparin cofactor activity (anti-IIa)	64	65	82–118
Heparan sulfate cofactor activity (anti-IIa)	60	68	84–120
Heparin cofactor activity (anti-Xa)	64	70	82–116
Pentasaccharide cofactor activity	60	66	84–116

* Values expressed as a percentage of that obtained from pooled plasma (20 normal samples).

Figure 1. Elution profile of heparin-Sepharose chromatography showing the resolution of antithrombin Rouen-II from normal antithrombin at pH 7.4. The proteins were eluted with an increasing linear NaCl gradient.

Table II. Antithrombin Levels* in Antithrombin Rouen-II Normal and Abnormal Fractions Separated by Heparin-Sepharose Chromatography

	Abnormal fraction	Normal fraction
Antithrombin antigen	60	40
Progressive anti-IIa activity	50	35
Heparin cofactor activity (anti-IIa)	<5	45
Pentasaccharide cofactor activity (anti-Xa)	<5	35

* Values expressed as a percentage of that obtained from pooled plasma (20 normal samples).

showed three tryptophan-staining peptides whereas Rouen-II had only two. This suggested that the abnormality had occurred within residues 47–53. The V8 maps gave two tryptophan peptides from both normal and abnormal antithrombins, with the peptide corresponding to residues 43–50 being shifted. The amino acid composition of the implicated peptides showed an arginine to be missing in the variant, but the identity of the new amino acid could not be unequivocally determined from the peptide maps. The tryptic peptide, residues 47–53, was isolated from both normal and Rouen-II digests by reversed phase HPLC using 49-mmol/liter phosphate buffer, pH 2.9, and an increasing concentration gradient of acetonitrile. The peptide was rerun on reversed phase HPLC in 0.1% trifluoroacetic acid with increasing acetonitrile. The peptides were monitored at 215 nm, and to detect the tryptophan-peptides, also at 280 nm. Amino acid sequence studies were performed on these peptides. These showed that arginine, which was at position 1 in the normal tryptic peptide, had been replaced by a serine. This corresponds to position 47 in the intact protein.

Discussion

Rouen-II is a new genetic variant of antithrombin with normal progressive inhibitory activity, but decreased cofactor activity, with both unfractionated or synthetic pentasaccharide heparins. As demonstrated by crossed immunoelectrophoresis with

both types of heparin, and also by heparin-Sepharose chromatography, this dysfunction is due to impaired heparin binding as has been previously demonstrated in other analogous variants (9–13, 20–23). The biochemical defect in Rouen-II was demonstrated by repeated peptide maps of both tryptic and V8 protease digests on thin layer plates, and by HPLC. These showed a single consistent difference in peptides overlapping residue 47. Sequence analysis showed this difference to be due to the replacement of the arginine normally present at position 47 by a serine. This mutation incidentally creates an unused oligosaccharide attachment site at position 45, i.e., Asn-Arg-Ser.

The identification of the mutation in antithrombin Rouen-II as 47 arginine to serine, is not a surprise. Among the seven other genetic variants so far identified (9–13, 24, 25) four with impaired heparin binding involve mutations of arginine 47: to cysteine in the independently observed variants Toyama (9), Tours (10), and Alger (11), and to histidine in Rouen-I (12). One reason for this recurrence of mutations at position 47 may be the susceptibility of the DNA codon for this arginine, CGT, to base substitutions; in particular, the replacement of arginine 47 by a cysteine is due to a thymine for cytosine substitution, a particularly frequent DNA mutation (26). Recurrent mutations in hemophilia A also provide evidence that CG dinucleotides are “hotspots” for mutations in man (27). However, the occurrence of three different mutations at the one site (to cysteine, to histidine, and to serine) all provide evidence of the critical role played by arginine 47 in the binding of heparin by antithrombin.

The results shown in Fig. 2 support the deduction that heparin binds to antithrombin by ionic bonding (salt-bridges) between the negatively charged sulfates of the heparin and positively charged basic amino acids (arginines and lysines) of antithrombin. Increasing salt concentrations compete for these bonds and diminish the heparin affinity particularly in the absence of arginine 47 in Rouen-II.

Several recent reports provide evidence that antithrombin can be activated on vascular heparin-like substances. This pathway could be responsible, in part, for the nonthrombogenic properties of endothelium (28). Among these substances, heparan sulfate proteoglycans bind with high affinity via sulfated saccharides similar to those of the unique pentasaccharide sequence of commercial heparin (29). The activation of Rouen-II by anticoagulant active heparan sulfate is defective and from this we deduce that arginine 47 is also a prime site for binding to endothelial proteoglycans. As we previously noticed (30), the incidence of thrombosis in heterozygous antithrombin variants with defective heparin binding is very low compared with that observed in quantitative defects or other types of variants. In the Rouen-II family, there is no definite history of thrombosis; the variant antithrombin retains its progressive activity, and as shown in Fig. 2, also has the potential to be activated by heparin though less readily than normal antithrombin. The observation of a greater concentration of the variant vs. the normal antithrombin (Table II) suggests increased consumption of the normal component and hence decreased functional activity of the variant. It is possible that this decreased in vivo functional activity of antithrombin Rouen-II was a factor that contributed to the coronary thrombosis of the propositus. Indeed, the homozygous patient for antithrombin Alger, with complete loss of heparan sulfate binding, does suffer from thromboembolic disease (22).

Figure 2. Antithrombin activity of purified normal antithrombin (0.2 μ g) and Rouen-II (0.2 μ g) in isotonic, 2 $\times$ isotonic, and 3 $\times$ isotonic buffers (pH 7.4) in the presence of 0.1, 0.5, and 5.0 U of heparin. Results are expressed as a percentage of normal antithrombin activity in isotonic buffer with 5 U of heparin added.

The results shown in Fig. 2 demonstrate that the defect in the Rouen-II variant is one of heparin (or heparan) binding and not of heparin activation. The identification of Rouen-II together with other variants of arginine 47, led us (with P. C. Christey and D. R. Boswell) to look at other basic residues that are uniquely conserved in the two heparin-activated serpins, antithrombin and heparin cofactor-II, and which might therefore be involved in the binding of heparin (31). Using computer alignments of the serpin family it is possible to determine homologous residues and project them (1) on the known crystallographic structure of the archetype of the family, alpha-1-antitrypsin (32). Seven such basic residues occur and five of them, including arginine 47, are plotted in Fig. 3 to give a proposed binding site for heparin. Further evidence for this binding site is given by the identification of asparagine 135 as the site of the oligosaccharide chain whose absence gives the increased natural affinity variant, beta-antithrombin (33), and also by the independent evidence of Blackburn that lysine 125 is directly involved in heparin binding (34).

The proposed binding site, as shown in Fig. 3, primarily involves the A and D helices, and is projected on the cleaved, postcomplex structure of alpha-1-antitrypsin (32). Reconstruction of the native structure in both antitrypsin and antithrombin involves a change in conformation but observations based on space-filling models make it unlikely that this transition is accompanied by gross alterations of the A and D helices (31).

Altogether then there is good evidence that heparin (and inferentially heparan) bind to a positively charged linear site extending across the molecule from arginine 47, as shown in Fig. 3. There is as yet no direct evidence as to how the binding

Figure 3. Proposed heparin binding site shown on a model of antithrombin projected on that of alpha-1-antitrypsin (from Carrell, Christey, and Boswell, with permission, reference 31). Positively charged residues uniquely conserved in antithrombin and heparin cofactor-II form a positive site stretching across the molecule from the A helix (47 Arg) to the D helix (125 Lys, 129 Arg, 132 Arg) and adjacent 133 Lys. Loss of the negatively charged oligosaccharide at position 135 gives increased heparin affinity (33). The crystallographic skeleton is that of alpha-1-antitrypsin cleaved at its active center. The arrows show, to the left, the position of the active center P_1 residue (Arg 393 in antithrombin) and, to the right, the P_1' residue (Ser 394 in antithrombin), which is bonded to the P_1 arginine in the native inhibitor.

of heparin activates the inhibitory function of the molecule; presumably there is an accompanying conformational change. Evidence for the events involved in this activation will come from the study of variants that bind heparin but do not activate it, and ultimately from crystallographic studies of antithrombin that show its three-dimensional conformation in the presence of heparin.

Acknowledgments

This work was supported in part by the Medical Research Councils of Great Britain and New Zealand.

References

1. Carrell, R. W., and D. R. Boswell. 1986. Serpins: the superfamily of plasma serine proteinase inhibitors. In *Proteinase Inhibitors*. A. Barrett, and G. Salvesen, editors. Elsevier, North Holland, Amsterdam, 403.
2. Thaler, E., and L. Lechner. 1981. Antithrombin III deficiency and thromboembolism. *Clin. Haematol.* 10:369-390.
3. Marcum, J. A., J. B. Mc Kenney, and R. D. Rosenberg. 1984. Acceleration of thrombin-antithrombin complex formation in rat hindquarters via heparin-like molecules bound to the endothelium. *J. Clin. Invest.* 74:341-350.
4. Marcum, J. A., L. Fritze, G. Galli, G. Karp, and R. D. Rosenberg. 1983. Microvascular heparin species with anticoagulant activity. *Am. J. Physiol.* 245:H725-H734.
5. Choay, J., M. Petitou, J. C. Lormeau, P. Sinay, B. Casu, and G. Gatti. 1983. Structure-activity relationship in heparin—A synthetic pentasaccharide with high affinity for antithrombin III and eliciting high anti-factor Xa activity. *Biochem. Biophys. Res. Commun.* 116:492-499.
6. Beetz, T., and C. A. A. Van Boeckel. 1986. Synthesis of an antithrombin binding heparin-like pentasaccharide lacking 6.0 sulphate at its reducing end. *Tetrahedron Lett.* 27:5589-5592.
7. Blackburn, M. N., and C. C. Sibley. 1980. The heparin binding site of antithrombin III. Evidence for a critical tryptophan residue. *J. Biol. Chem.* 255:824-826.
8. Pecon, J. M., and M. N. Blackburn. 1984. Pyridoxylation of essential lysines in the heparin-binding site of antithrombin III. *J. Biol. Chem.* 259:935-936.
9. Koide, T., S. Odani, K. Tokahashi, T. Ono, and N. Sakuragawa. 1984. Antithrombin III Toyama: replacement of arginine 47 by cysteine in hereditary abnormal antithrombin III that lacks heparin-binding ability. *Proc. Natl. Acad. Sci. USA.* 81:289-293.
10. Duchange, N., J. F. Chassé, G. N. Gohen, and M. M. Zakin. 1987. Molecular characterization of the antithrombin III Tours deficiency. *Thromb. Res.* 45:115-121.
11. Brunel, F., N. Duchange, A. M., Fischer, G. N. Cohen, and M. M. Zakin. 1987. Antithrombin III Alger: a new case of Arg 47 → Cys Mutation. *Am. J. Hematol.* 25:223-224.
12. Owen, M. C., J. Y. Borg, C. Soria, J. Soria, J. Caen, and R. W. Carrel. 1987. Heparin binding defect in a new antithrombin III variant: Rouen, 47 Arg to His. *Blood.* 69:1275-1279.
13. Chang, J. Y., and T. H. Tran. 1986. Antithrombin III Basel. Identification of a Pro-Leu substitution in a hereditary abnormal antithrombin with impaired heparin cofactor activity. *J. Biol. Chem.* 261:1174-1176.
14. Laurell, C. B. 1966. Quantitative estimation of proteins by electrophoresis in agarose-containing antibodies. *Anal. Biochem.* 15:45-52.
15. Aiach, M., M. Nora, J. N. Fiessinger, M. Roncato, D. François, and M. A. Gelas. 1985. A functional abnormal antithrombin III (AT III) deficiency: AT III Charleville. *Thromb. Res.* 39:559-570.
16. Odegard, O. R., and V. Abildgaard. 1976. Antifactor Xa activity measured with amidolytic methods. *Haemostasis.* 5:265-276.

17. Aiach, M., M. Léon, A. Michaud, and L. Capron. 1983. Adaptation of synthetic peptide substrate-based assays on a discrete analyser. *Semin. Thromb. Hemostasis*. 9:206-216.
18. Casu, B., E. A. Johnson, M. Mantovani, B. Mulloy, P. Oreste, R. Pescador, G. Prino, G. Torri, and G. Zoppeti. 1983. Correlation between structure, fat-clearing and anticoagulant properties of heparins and heparan sulphates. *Drug Res.* 33:135-142.
19. Sas, G., D. S. Pepper, and J. D. Cash. 1975. Further investigations on antithrombin in the plasma of patients with the abnormality "antithrombin III Budapest." *Thromb. Diath. Haemorrh.* 38:494-503.
20. Wolf, M., C. Boyer, J. M. Lavergne, and M. J. Larrieu. 1982. A new familial variant of antithrombin III. *Br. J. Haematol.* 51:284-295.
21. Boyer, C., M. Wolf, J. Vedrenne, D. Meyer, and M. J. Larrieu. 1986. Homozygous variant of antithrombin III: AT III Fontainebleau. *Thromb. Haemostasis*. 56:18-22.
22. Fischer, A. M., S. Beguin, C. Sternberg, and M. D. Dautzenberg. 1987. Comparative effect of heparin and heparan sulphate on two abnormal antithrombin-III type 3 variants. *Br. J. Haematol.* 66:213-217.
23. De Moerloose, P. A., G. Reber, Ph. Vernet, Ph. Minazio, and C. A. Bouvier. 1987. Antithrombin-III Geneva: a new hereditary abnormal AT-III with defective heparin cofactor activity. *Thromb. Haemostasis*. 57:154-157.
24. Stephens, A. W., B. S. Thalley, and C. H. W. Hirs. 1987. Antithrombin-III Denver, a reactive site variant. *J. Biol. Chem.* 262:1044-1048.
25. Devraj-Kizuk, R., E. V. Prochownik, D. H. K. Chui, and M. A. Blajchman. 1986. Molecular pathology of a mutant antithrombin-III gene, AT-III Hamilton. *Blood*. 1(Suppl.):345a.
26. Coulondre, C., J. H. Miller, P. J. Farabaugh, and W. Gilbert. 1978. Molecular basis of base substitution hotspots in *Escherichia coli*. *Nature (Lond.)*. 274:775-780.
27. Youssoufian, H., H. H. Kazazian, D. G. Phillips, S. Aronis, G. Tsiftis, V. A. Brown, and S. E. Antonarakis. 1986. Recurrent mutations in haemophilia A give evidence for CpG mutation hotspots. *Nature (Lond.)*. 324:380-382.
28. Marcum, J. A., and R. D. Rosenberg. 1985. Heparin-like molecules with anticoagulant activity are synthesized by cultured endothelial cells. *Biochem. Biophys. Res. Commun.* 126:365-372.
29. Marcum, J. A., D. H. Athe, L. M. S. Fritze, P. Nawroth, D. Stern, and R. D. Rosenberg. 1986. Cloned bovine aortic endothelial cells synthesize anticoagulant active heparin sulphate proteoglycan. *J. Biol. Chem.* 261:7507-7517.
30. Borg, J. Y., J. Soria, C. Soria, M. Legendre, H. Piguët, M. Monconduit. 1985. Antithrombin-III variants Rouen with defective heparin-cofactor activities and low thrombotic incidence. *Thromb. Haemostasis*. 54. *Proc. Xth Int. Congr. Thromb. Haemostasis*. 88:517.
31. Carrell, R. W., P. B. Christey, and D. R. Boswell. 1987. Serpins: antithrombin and other inhibitors of coagulation and fibrinolysis. Evidence from amino acid sequence. In *Thrombosis and Haemostasis*. M. Verstraedt, J. Vermeylen, R. Lijnen, and J. Arnout, editors. Leuven University Press, Belgium. 1-15.
32. Loebermann, H., R. Tokaoka, J. Diesenhofer, and R. Huber. 1984. Human alpha-1-proteinase inhibitor: crystal structure analysis of two crystal modifications, molecular model and preliminary analysis of the implications for function. *J. Mol. Biol.* 177:531-556.
33. Brennan, S. O., P. M. George, and R. E. Jordan. 1987. Physiological variant of antithrombin-III lacks carbohydrate sidechain at Asn 135. *FEBS (Fed. Eur. Biochem. Soc.) Lett.* 219:431-436.
34. Peterson, C. B., C. M. Noyes, J. M. Pecon, F. C. Church, and M. N. Blackburn. 1987. Lysine-125 is essential for heparin binding to antithrombin. *Thromb. Haemostasis*. 58(1):970.